A recent study on the predictive value of PD-1 IHC (coupled with image analysis) in patients undergoing treatment with PD-1 inhibitors (nivolumab and pembrolizumab) for NSCLC patients showed that PD-1 density is a better predictive biomarker for durable clinical benefit in these two NSCLC cohorts treated with PD-1 blockade than PD-L1 score [90]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.